MicroRNA-21 (miRNA-21), a critical oncogenic biomarker, poses detection challenges due to low abundance and limitations of conventional methods. Herein, we developed a novel CRISPR-SDA biosensing platform by integrating strand displacement amplification (SDA) with CRISPR-Cas12a, leveraging SDA's efficient isothermal amplification of miRNA-21 and Cas12a's precise target recognition and trans-cleavage activity for signal amplification. Optimized conditions achieved high sensitivity with a detection limit of 10.1 fM and segmented linear ranges of 0.05-25 pM and 25-500 pM. It showed excellent selectivity against other miRNAs and anti-interference in complex matrices (e.g., salmon sperm DNA). Spike recovery experiments in fetal bovine serum yielded recoveries of 92 ± 7.8% to 105.6 ± 3.3%, confirming its reliability in complex biological samples. This CRISPR-SDA platform overcomes the drawbacks of conventional methods, enabling rapid, sensitive, and equipmentfriendly detection. It holds great potential for early cancer diagnosis and point-of-care testing, and provides a versatile framework for detecting other disease-associated nucleic acids.

You have access to this article

Please wait while we load your content... Something went wrong. Try again?